AGENUS INC Nonfinancial Liabilities Fair Value Disclosure
AGENUS INC (AGEN) had Nonfinancial Liabilities Fair Value Disclosure of $318.00 thousand as of 2025-06-30, per its 10-Q filed 2025-08-11.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Net Asset (Liability)
us-gaap:NonfinancialLiabilitiesFairValueDisclosure · last filed 2026-03-16
- 2025-06-30: Nonfinancial Liabilities Fair Value Disclosure $318.00K.
- 2025-03-31: Nonfinancial Liabilities Fair Value Disclosure $387.00K.
- 2024-12-31: Nonfinancial Liabilities Fair Value Disclosure $387.00K.
- 2024-09-30: Nonfinancial Liabilities Fair Value Disclosure $2.48M.
| Period end | Nonfinancial Liabilities Fair Value Disclosure |
|---|---|
| 2025-06-30 | $318.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $387.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $387.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $2.48M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $4.34M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $318.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $318.00K 10-K · filed 2025-03-17 |
| 2023-09-30 | $476.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $476.00K 10-Q · filed 2023-08-08 |
| 2022-12-31 | $874.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $739.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $746.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.15M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.69M 10-K · filed 2023-03-16 |
| 2021-09-30 | $3.74M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $4.13M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $9.16M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $10.21M 10-K · filed 2022-03-01 |
| 2020-09-30 | $13.64M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $11.44M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $4.46M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $8.84M 10-K · filed 2021-03-16 |
| 2019-09-30 | $4.22M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $6.00M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $5.79M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $3.04M 10-K · filed 2020-03-16 |
| 2018-09-30 | $2.92M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $3.10M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $9.39M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $4.37M 10-K · filed 2019-03-18 |
| 2017-09-30 | $7.68M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $6.50M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $7.37M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $7.56M 10-K · filed 2018-03-16 |
| 2015-12-31 | $5.61M 10-K · filed 2017-03-16 |
| 2015-06-30 | $32.39M 10-Q · filed 2015-08-03 |
| 2015-03-31 | $18.76M 10-Q · filed 2015-05-01 |
| 2014-12-31 | $31.70M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |